Northwest & Ethical Investments L.P. Trims Stake in Boston Scientific Corporation $BSX

Northwest & Ethical Investments L.P. decreased its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 2.4% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 72,550 shares of the medical equipment provider’s stock after selling 1,800 shares during the quarter. Northwest & Ethical Investments L.P.’s holdings in Boston Scientific were worth $7,779,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the business. Russell Investments Group Ltd. boosted its position in Boston Scientific by 9.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,442,640 shares of the medical equipment provider’s stock valued at $154,818,000 after buying an additional 120,648 shares during the period. Inceptionr LLC bought a new position in shares of Boston Scientific during the 2nd quarter worth $1,115,000. J.W. Cole Advisors Inc. raised its holdings in shares of Boston Scientific by 176.9% in the second quarter. J.W. Cole Advisors Inc. now owns 22,234 shares of the medical equipment provider’s stock valued at $2,388,000 after acquiring an additional 14,203 shares in the last quarter. Advisors Asset Management Inc. raised its holdings in shares of Boston Scientific by 17.3% in the 2nd quarter. Advisors Asset Management Inc. now owns 42,032 shares of the medical equipment provider’s stock valued at $4,515,000 after purchasing an additional 6,199 shares in the last quarter. Finally, Laurel Wealth Advisors LLC boosted its stake in shares of Boston Scientific by 25,858.3% during the second quarter. Laurel Wealth Advisors LLC now owns 3,115 shares of the medical equipment provider’s stock valued at $335,000 after purchasing an additional 3,103 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

BSX has been the topic of several recent research reports. BTIG Research reaffirmed a “buy” rating and set a $132.00 target price on shares of Boston Scientific in a research report on Friday, November 21st. Morgan Stanley raised their price target on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 11th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, October 8th. Finally, Barclays boosted their price target on Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a report on Thursday, October 2nd. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific has an average rating of “Buy” and an average price target of $123.77.

Insider Transactions at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares in the company, valued at approximately $17,561,336.74. This represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the transaction, the director owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 175,782 shares of company stock worth $17,742,314 over the last ninety days. 0.50% of the stock is owned by insiders.

Boston Scientific Stock Performance

BSX opened at $101.14 on Thursday. The firm has a market capitalization of $149.93 billion, a PE ratio of 54.08, a PEG ratio of 2.02 and a beta of 0.58. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50. The firm’s 50-day moving average price is $99.04 and its 200 day moving average price is $102.29.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The firm had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter last year, the firm earned $0.63 earnings per share. The business’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, sell-side analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.